Weight stabilisation is associated with improved survival duration and quality of life in unresectable pancreatic cancer

Clinical Nutrition

Volumn 23, Issue 2, 2004, Pages 239-247

  Davidson, Wendy ^a,b   Ash, Susan ^a   Capra, Sandra ^b   Bauer, Judith ^b,c,j   Fearon, K C H ^d   von Meyenfeldt, M F ^e   Roy, A ^f   Gouma, D J ^g   Giacosa, A ^h   Van Gossum, A ⁱ   Ash, S ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c Wesley Research Institute   (Australia)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^j WESLEY HOSPITAL   (Australia)

more..

Author keywords

Cachexia; Nutrition; Pancreatic neoplasms; Quality of life; Survival; Weight loss

Indexed keywords

C REACTIVE PROTEIN; OMEGA 3 FATTY ACID; PHOSPHOLIPID;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BODY WEIGHT DISORDER; CALORIC INTAKE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; GENDER; HUMAN; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PANCREAS CANCER; PREDICTION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL ANALYSIS; SURVIVAL TIME; WEIGHT REDUCTION;

EID: 12144287683     PISSN: 02615614     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clnu.2003.07.001     Document Type: Article

References (47)

1. DeWys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69: 491-7.
2. Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997;75:106-9.
3. Evans WK, Nixon DW, Daly JM, et al. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 1987;5: 113-24.
4. Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol 1993;11:2043-9.
5. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
6. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: state-of-the-art care. CA Cancer J Clin 2000;50: 241-68.
7. Lillemoe KD. Palliative therapy for pancreatic cancer. Surg Oncol Clin North Am 1998;7:199-216.
8. Cooperman AM, Kini S, Snady H, Bruckner H, Chamberlain RS. Current surgical therapy for carcinoma of the pancreas. J Clin Gastroenterol 2000;31:107-13.
9. Alter CL. Palliative and supportive care of patients with pancreatic cancer. Semin Oncol 1996;23:229-40.
10. Ellison NM, Chevlen E, Still CD, Dubagunta S. Supportive care for patients with pancreatic adenocarcinoma: Symptom control and nutrition. Hematol Oncol Clin North Am 2002;16:105-21.
11. Falconer JS, Fearon KC, Ross JA, et al. Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 1995;75:2077-82.
12. Terwee CB, Nieveen Van Dijkum EJ, Gouma DJ, et al. Pooling of prognostic studies in cancer of the pancreatic head and periampullary region: The triple-P study. Triple-P study group. Eur J Surg 2000;166:706-12.
13. Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 1998;34:503-9.
14. van den Bosch RP, van der Schelling GP, Klinkenbijl JH, Mulder PG, van Blankenstein M, Jeekel J. Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann Surg 1994;219:18-24.
15. Krech RL, Walsh D. Symptoms of pancreatic cancer. J Pain Symptom Manage 1991;6:360-7.
16. Ottery F. Supportive nutritional management of the patient with pancreatic cancer. Oncology (Huntingt) 1996;10: 26-32.
17. Wigmore SJ, Plester CE, Ross JA, Fearon KC. Contribution of anorexia and hypermetabolism to weight loss in anicteric patients with pancreatic cancer. Br J Surg 1997;84: 196-7.
18. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994;219:325-31.
19. Karayiannakis AJ, Syrigos KN, Polychronidis A, Pitiakoudis M, Bounovas A, Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 2001;21:1355-8.
20. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature 1996;379:739-42.
21. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998;58: 2359-65.
22. Wigmore SJ, Todorov PT, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor. Br J Surg 2000;87:53-8.
23. Cella DF. Overcoming difficulties in demonstrating health outcome benefits. J Parenter Enteral Nutr 1992;16: 106S-11S.
24. Aaronson NK. Quality of life research in cancer clinical trials: A need for common rules and language. Oncology (Huntingt) 1990;4:59-66.
25. Wade EV, Jain R. Nutritional support: Enhancing the quality of life of the terminally ill patient with cancer. J Am Diet Assoc 1984;84:1044-5.
26. Fearon K, von Meyenfeldt M, Moses A, et al. The effect of a protein and energy dense, n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut 2003, in press.
27. Rosenbaum K, Wang J, Pierson Jr RN, Kotler DP. Time-dependent variation in weight and body composition in healthy adults. J Parenter Enteral Nutr 2000;24:52-5.
28. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85: 365-76.
29. Fayers P, Aaronson N, Bjordal K, Sullivan M. EORTC QLQ-C30 scoring manual. Belgium: EORTC Data Center; 1999.
30. O'Gorman P, McMillan DC, McArdle CS. Impact of weight loss, appetite, and the inflammatory response on quality of life in gastrointestinal cancer patients. Nutr Cancer 1998;32: 76-80.
31. King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res 1996;5: 555-67.
32. Wigmore SJ, Falconer JS, Plester CE, et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995;72:185-8.
33. Rebro SM, Patterson RE, Kristal AR, Cheney CL. The effect of keeping food records on eating patterns. J Am Diet Assoc 1998;98:1163-5.
34. Martin LJ, Su W, Jones PJ, Lockwood GA, Tritchler DL, Boyd NF. Comparison of energy intakes determined by food records and doubly labeled water in women participating in a dietary-intervention trial. Am J Clin Nutr 1996;63: 483-90.
35. Black AE, Goldberg GR, Jebb SA, Livingstone MB, Cole TJ, Prentice AM. Critical evaluation of energy intake data using fundamental principles of energy physiology: 2. Evaluating the results of published surveys. Eur J Clin Nutr 1991; 45:583-99.
36. Livingstone MB, Prentice AM, Strain JJ, et al. Accuracy of weighed dietary records in studies of diet and health. Br Med J 1990;300:708-12.
37. Capra S, Bauer J, Davidson W, Ash S. Nutritional therapy for cancer-induced weight loss. Nutr Clin Pract 2002;17:210-3.
38. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80-6.
39. McMillan DC, Wigmore SJ, Fearon KC, O'Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer 1999;79:495-500.
40. Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998;25:53-7.
41. Inui A. Cancer anorexia-cachexia syndrome: Are neuropeptides the key? Cancer Res 1999;59:4493-501.
42. Langer CJ, Hoffman JP, Ottery FD. Clinical significance of weight loss in cancer patients: Rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition 2001;17:S1-20.
43. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999;17:3299-306.
44. Klein S, Koretz RL. Nutrition support in patients with cancer: What do the data really show? Nutr Clin Pract 1994;9: 91-100.
45. Rhodes VA, McDaniel RW. Nausea, vomiting, and retching: complex problems in palliative care. CA Cancer J Clin 2001;51:232-48.
46. Held-Warmkessel J, Volpe H, Waldman AR. Symptom management for patients with pancreatic cancer. Clin J Oncol Nurs 1998;2:135-9.
47. Chlebowski RT, Palomares MR, Lillington L, Grosvenor M. Recent implications of weight loss in lung cancer management. Nutrition 1996;12:S43-7.